Large Antibody For Virus Efforts
Lab Reagents
Human IgG antibody Laboratories manufactures the large antibody for virus efforts reagents distributed by Genprice. The Large Antibody For Virus Efforts reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact virus Antibody. Other Large products are available in stock. Specificity: Large Category: Antibody Group: For Virus
Mouse antibody for Parainfluenza virus |
|||
1259 | Virostat | 100 ug | EUR 431.93 |
Description: This is Mouse monoclonal FITC conjugated antibody against Parainfluenza virus type 3 for WB, ELISA. |
Mouse antibody for Vaccinia virus |
|||
8112 | Virostat | 100 ug | EUR 386.26 |
Description: This is purified Mouse monoclonal antibody against Vaccinia virus for WB, ELISA. |
Mouse antibody for Vaccinia virus |
|||
8118 | Virostat | 100 ug | EUR 386.26 |
Description: This is purified Mouse monoclonal antibody against Vaccinia virus for WB, ELISA. |
Simian Virus 40 Large Tumor Antigen Amino-Terminal Peptide |
|||
5-01932 | CHI Scientific | 4 x 5mg | Ask for price |
Simian Virus 40 Large Tumor Antigen Amino-Terminal Peptide |
|||
20-abx266097 | Abbexa |
|
|
Recombinant (E.Coli) purified Measles virus Large Polymerase (2059-2183) |
|||
RP-1612 | Alpha Diagnostics | 100 ug | EUR 416.4 |
Recombinant (E.Coli) purified Measles virus Large Polymerase (58-149) |
|||
RP-1613 | Alpha Diagnostics | 100 ug | EUR 416.4 |
Anti-LARGE antibody |
|||
PAab04697 | Lifescience Market | 100 ug | EUR 463.2 |
anti- LARGE antibody |
|||
FNab04697 | FN Test | 100µg | EUR 658.5 |
Description: Antibody raised against LARGE |
Anti-LARGE antibody |
|||
STJ11100708 | St John's Laboratory | 50 µl | EUR 344.4 |
Description: This gene, which is one of the largest in the human genome, encodes a member of the N-acetylglucosaminyltransferase gene family. It encodes a glycosyltransferase which participates in glycosylation of alpha-dystroglycan, and may carry out the synthesis of glycoprotein and glycosphingolipid sugar chains. It may also be involved in the addition of a repeated disaccharide unit. Mutations in this gene cause MDC1D, a novel form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of alpha-dystroglycan. Alternative splicing of this gene results in two transcript variants that encode the same protein. |
Perlecan Antibody (Large) |
|||
V2600-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: This mAb specifically precipitates heterogeneous material of high MW, identified as perlecan, a major heparan-sulfate proteoglycan (HSPG) within all basement membranes and cell surfaces. It does not cross-react with laminin, fibronectin, or dermatran sulfate proteoglycan. Because of perlecan s strategic location and ability to store and protect growth factors, it has been strongly implicated in the control of tumor cell growth and metastatic behavior. Perlecan possesses angiogenic and growth-promoting attributes primarily by acting as a co-receptor for basic fibroblast growth factor (FGF-2). Suppression of perlecan causes substantial inhibition of neoplastic growth and neovascularization. Thus, perlecan is a potent inducer of neoplasm growth and angiogenesis in vivo and therapeutic interventions targeting this key modulator of tumor progression may improve neoplastic treatment. |
Perlecan Antibody (Large) |
|||
V2600-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
Description: This mAb specifically precipitates heterogeneous material of high MW, identified as perlecan, a major heparan-sulfate proteoglycan (HSPG) within all basement membranes and cell surfaces. It does not cross-react with laminin, fibronectin, or dermatran sulfate proteoglycan. Because of perlecan s strategic location and ability to store and protect growth factors, it has been strongly implicated in the control of tumor cell growth and metastatic behavior. Perlecan possesses angiogenic and growth-promoting attributes primarily by acting as a co-receptor for basic fibroblast growth factor (FGF-2). Suppression of perlecan causes substantial inhibition of neoplastic growth and neovascularization. Thus, perlecan is a potent inducer of neoplasm growth and angiogenesis in vivo and therapeutic interventions targeting this key modulator of tumor progression may improve neoplastic treatment. |
Perlecan Antibody (Large) |
|||
V2600IHC-7ML | NSJ Bioreagents | 7 ml | EUR 499 |
Description: This mAb specifically precipitates heterogeneous material of high MW, identified as perlecan, a major heparan-sulfate proteoglycan (HSPG) within all basement membranes and cell surfaces. It does not cross-react with laminin, fibronectin, or dermatran sulfate proteoglycan. Because of perlecan s strategic location and ability to store and protect growth factors, it has been strongly implicated in the control of tumor cell growth and metastatic behavior. Perlecan possesses angiogenic and growth-promoting attributes primarily by acting as a co-receptor for basic fibroblast growth factor (FGF-2). Suppression of perlecan causes substantial inhibition of neoplastic growth and neovascularization. Thus, perlecan is a potent inducer of neoplasm growth and angiogenesis in vivo and therapeutic interventions targeting this key modulator of tumor progression may improve neoplastic treatment. |
Perlecan Antibody (Large) |
|||
V2600SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: This mAb specifically precipitates heterogeneous material of high MW, identified as perlecan, a major heparan-sulfate proteoglycan (HSPG) within all basement membranes and cell surfaces. It does not cross-react with laminin, fibronectin, or dermatran sulfate proteoglycan. Because of perlecan s strategic location and ability to store and protect growth factors, it has been strongly implicated in the control of tumor cell growth and metastatic behavior. Perlecan possesses angiogenic and growth-promoting attributes primarily by acting as a co-receptor for basic fibroblast growth factor (FGF-2). Suppression of perlecan causes substantial inhibition of neoplastic growth and neovascularization. Thus, perlecan is a potent inducer of neoplasm growth and angiogenesis in vivo and therapeutic interventions targeting this key modulator of tumor progression may improve neoplastic treatment. |
Perlecan Antibody (Large) |
|||
V2601-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: This mAb specifically precipitates heterogeneous material of high MW, identified as perlecan, a major heparan-sulfate proteoglycan (HSPG) within all basement membranes and cell surfaces. It does not cross-react with laminin, fibronectin, or dermatran sulfate proteoglycan. Because of perlecan s strategic location and ability to store and protect growth factors, it has been strongly implicated in the control of tumor cell growth and metastatic behavior. Perlecan possesses angiogenic and growth-promoting attributes primarily by acting as a co-receptor for basic fibroblast growth factor (FGF-2). Suppression of perlecan causes substantial inhibition of neoplastic growth and neovascularization. Thus, perlecan is a potent inducer of neoplasm growth and angiogenesis in vivo and therapeutic interventions targeting this key modulator of tumor progression may improve neoplastic treatment. |
Perlecan Antibody (Large) |
|||
V2601-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
Description: This mAb specifically precipitates heterogeneous material of high MW, identified as perlecan, a major heparan-sulfate proteoglycan (HSPG) within all basement membranes and cell surfaces. It does not cross-react with laminin, fibronectin, or dermatran sulfate proteoglycan. Because of perlecan s strategic location and ability to store and protect growth factors, it has been strongly implicated in the control of tumor cell growth and metastatic behavior. Perlecan possesses angiogenic and growth-promoting attributes primarily by acting as a co-receptor for basic fibroblast growth factor (FGF-2). Suppression of perlecan causes substantial inhibition of neoplastic growth and neovascularization. Thus, perlecan is a potent inducer of neoplasm growth and angiogenesis in vivo and therapeutic interventions targeting this key modulator of tumor progression may improve neoplastic treatment. |
Perlecan Antibody (Large) |
|||
V2601IHC-7ML | NSJ Bioreagents | 7 ml | EUR 499 |
Description: This mAb specifically precipitates heterogeneous material of high MW, identified as perlecan, a major heparan-sulfate proteoglycan (HSPG) within all basement membranes and cell surfaces. It does not cross-react with laminin, fibronectin, or dermatran sulfate proteoglycan. Because of perlecan s strategic location and ability to store and protect growth factors, it has been strongly implicated in the control of tumor cell growth and metastatic behavior. Perlecan possesses angiogenic and growth-promoting attributes primarily by acting as a co-receptor for basic fibroblast growth factor (FGF-2). Suppression of perlecan causes substantial inhibition of neoplastic growth and neovascularization. Thus, perlecan is a potent inducer of neoplasm growth and angiogenesis in vivo and therapeutic interventions targeting this key modulator of tumor progression may improve neoplastic treatment. |